We gebruiken cookies om ervoor te zorgen dat onze site zo soepel mogelijk draait. Als je doorgaat met het gebruiken van deze site, gaan we er vanuit dat je ermee instemt.
VieCuri heeft nu als 1e ziekenhuis van Nederland een ultrasnelle PTH-meter die binnen 5 minuten een uitslag kan leveren. Dat betekent dat de chirurg al tijdens de operatie duidelijkheid heeft over al dan niet dalende PTH-waarden. “Voorheen was dit een tijdrovend proces, met het risico dat de patiënt mogelijk een tweede operatie nodig had. Met […]
We thank Alexander Sherry and colleagues and Sheng Zhang and colleagues for their interest in the First International Randomized study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP) phase 2 trial methodology.
The completion of the First International Randomized study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP)1 trial by Eric Baudin and colleagues is indeed a success. However, the adverse events of sunitinib are substantial in comparison with the placebo group: dose interruption was reported in 27 (69%) of 39 people in the experimental group versus six (15%) of 39 in the control group, at least one dose reduction was reported in 17 (44%) people in the experimental group versus one (3%) person in the control group, and treatment discontinuation due to adverse events was reported in five (14%) of 35 patients in the experimental group.
The phase 2, randomised, non-comparative First International Randomized study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP) by Eric Baudin and colleagues1 investigated sunitinib versus placebo in patients with metastatic phaeochromocytomas and paragangliomas. We commend the authors for accruing a rare patient population to an important international and multicentre study. However, this study's interpretation is made challenging by the design as a randomised non-comparative trial.
Primary immune thrombocytopenia is an autoimmune disease in which autoreactive B cells play a crucial role in pathogenesis by producing autoantibodies primarily directed against platelet surface glycoproteins (eg, glycoprotein IIb/IIIa; fibrinogen receptor) that trigger platelet destruction, resulting in severe thrombocytopenia. The annualised incidence of primary immune thrombocytopenia is approximately 3·3 cases per 100?000 people among adults.1 Despite several treatment options, including approved thrombopoietin receptor agonists and commonly used antibody-reducing approaches—such as B-cell depletion with the anti-CD20 monoclonal antibody rituximab, BTK inhibitors, SYK inhibitors, corticosteroids, and splenectomy—a subset of patients develop refractory immune thrombocytopenia.
The American Diabetes Association, the nation's leading voluntary health organization fighting to end diabetes and helping people thrive, has announced a new suite of resources to support improved care for those living with obesity.